Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Donate to Science & Enterprise

Please share Science & Enterprise

Patent Issued for Crispr-Edited Viruses in Microbiome

Crispr-Cas9

A biotechnology company developing gene-edited therapies for bacterial infections in the gut received a U.S. patent for viruses engineered as treatments. . . . → Read More: Patent Issued for Crispr-Edited Viruses in Microbiome

Start-Up Licenses Gene-Edited Drug Discovery Tech.

African clawed frog

A new company is acquiring a technology using genome-edited tadpoles that finds current drugs addressing precise genetic conditions underlying rare diseases. . . . → Read More: Start-Up Licenses Gene-Edited Drug Discovery Tech.

Cannabinoid Synthesis Process Licensed to Spin-Off Company

DNA illustration

A genetic technology for synthesizing cannabinoid compounds without cannabis cells was licensed to a company spun-off from the lab that developed the process. . . . → Read More: Cannabinoid Synthesis Process Licensed to Spin-Off Company

Univ. Labs Ink Licensing Deals for Covid-19 Tests

Home testing station

Two companies agreed to license technologies from academic labs in the U.S. and U.K. for developing faster and more sensitive at-home tests for Covid-19 infections. . . . → Read More: Univ. Labs Ink Licensing Deals for Covid-19 Tests

Patent Issued for Anti-Bacterial Viruses with Crispr Payloads

Crispr graphic

A biotechnology company received a patent for its engineered viruses to deliver gene-edited treatments to combat bacterial infections in the microbiome. . . . → Read More: Patent Issued for Anti-Bacterial Viruses with Crispr Payloads

Women’s Health Companies Partner on New Contraceptive

Women silhouettes

Two companies working in women’s reproductive health are developing a new non-hormonal contraceptive that works in cervical mucous membranes. . . . → Read More: Women’s Health Companies Partner on New Contraceptive

Biotech in $1.5B Gene-Editing Tech License Deal

Sickle cell illustration

A biotechnology company is licensing a gene-editing enzyme to Novartis to create treatments for inherited blood disorders such as sickle cell disease. . . . → Read More: Biotech in $1.5B Gene-Editing Tech License Deal

Companies Partner on Implanted Diabetes Beta Cell Device

Diabetes blood glucose test

A company developing implants that release cell therapies is collaborating with a producer of regenerative stem cells to dispense insulin for people with diabetes. . . . → Read More: Companies Partner on Implanted Diabetes Beta Cell Device

Univ. Lab Licenses Protein for Vaccine Patch

Nanopatch system

A company developing a needle patch for vaccine delivery is acquiring the rights to a synthetic SARS-Cov-2 spike protein for its Covid-19 vaccine patch. . . . → Read More: Univ. Lab Licenses Protein for Vaccine Patch

Drug Discovery Biotech Inks Partnering Deal, Gains $175M

Gregory Verdine

A biotechnology company discovering protein therapies in fungi is collaborating with drug maker GlaxoSmithKline to find new small molecule drugs. . . . → Read More: Drug Discovery Biotech Inks Partnering Deal, Gains $175M